3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Breast Neoplasms
14
Neoplasms
10
Head and Neck Neoplasms
8
Carcinoma, Squamous Cell
8
Lung Neoplasms
7
Leukemia, Myeloid, Acute
7
Glioblastoma
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Recurrence
5
Pancreatic Neoplasms
5
Melanoma
5
Leukemia
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Fallopian Tube Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Rectal Neoplasms
3
Lymphoma, Follicular
3
Colonic Neoplasms
3
Brain Neoplasms
3
Treatment
2
Sarcoma
2
Pleural Effusion, Malignant
2
Pharyngeal Neoplasms
2
Interventions
Rituximab
40
Cyclophosphamide
29
Etoposide
15
Doxorubicin
14
Vincristine
13
Prednisone
13
ibrutinib
10
fludarabine
10
fludarabine phosphate
8
Cytarabine
8
Mycophenolic Acid
7
Bortezomib
7
Lenalidomide
6
Carmustine
6
pembrolizumab
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Inotuzumab Ozogamicin
5
Whole-Body Irradiation
4
Tacrolimus
4
Carboplatin
4
CT-P10
4
Brentuximab Vedotin
4
Antilymphocyte Serum
4
tositumomab I-131
3
tocilizumab
3
tazemetostat
3
obinutuzumab
3
idelalisib
3
etoposide phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, B-Cell
×
Drug Therapy
×
Clear all
NCT03570892
2026-05-14
BELINDA
Novartis
Phase 3
Completed
330 enrolled
10 charts